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INTRODUCTION
Post-transplant lymphoproliferative disorders (PTLD) are
a heterogeneous group of lymphoproliferative disorders asso-
ciated with the immunosuppression in recipients of solid organ
or allogeneic stem cell transplantation. The incidence of PTLD
varies from 1% to 20% according to the organ transplanted
(1). The Epstein Barr virus (EBV) plays an important role in
the pathogenesis of PTLD.
PTLD is typically classified into three major categories:
early lesions, polymorphic PTLD, and monomorphic PTLD
(2). Monomorphic PTLD is defined by the fulfillment of the
criteria for one of the recognized types of lymphoma. The
majority of monomorphic PTLD cases is non-Hodgkin’s lym-
phoma of B-cell origin; in contrast, T-cell lymphoma and
Hodgkin’s disease are rare. The recently updated World Health
Organization classification separated classical Hodgkin lym-
phoma type PTLD from monomorphic PTLD (3). 
Although there are several reports on PTLD, there are few
data on monomorphic PTLD in Korea. The goal of our study
was to investigate the incidence, clinical manifestation, treat-
ment, and outcomes of monomorphic PTLD, including Hodg-
kin’s lymphoma, in Korea.
MATERIALS AND METHODS
This study included all patients who were diagnosed with
monomorphic PTLD confirmed by tissue diagnosis among
5,817 recipients of solid organ or allogeneic stem cell trans-
plantation from five institutions in Korea between January
1987 and January 2009. The medical records of these patients
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Clinical Characteristics of Monomorphic Post-transplant 
Lymphoproliferative Disorders
Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group
of lymphoproliferative disorders associated with immunosuppression and Epstein-
Barr virus infection. PTLD is classified into three major categories: early lesions,
polymorphic PTLD, and monomorphic PTLD. The majority of monomorphic PTLD
cases are non-Hodgkin’s lymphoma of B-cell origin. This retrospective study was
conducted to investigate the incidence, clinical manifestation, treatment, and out-
comes of monomorphic PTLD among 5,817 recipients of solid organ or allogeneic
hematopoietic stem cell transplantation from five institutions. Fourteen patients with
monomorphic PTLD were identified (male:female 11:3; median age 42.6 yr, range
24-60). The overall incidence rate was 0.24%. The most common disease type was
diffuse large B cell lymphoma (n=7). The median time between the transplant and
diagnosis of PTLD was 85.8 months. However, all cases of PTLD after allogeneic
hematopoietic stem cell transplantation occurred within 1 yr after transplantation. Ten
of the 14 patients had EBV-positive tumor. Fourteen patients received combination
systemic chemotherapy and four patients were treated with radiation therapy. Ten
patients achieved a complete response (CR) and two patients a partial response
(PR). The median follow-up period for surviving patients was 36.6 months. Nine
patients remain alive (eight CR, one PR). Nine of 11 solid organ transplantations
preserved graft function. The present study indicates a lower incidence rate and a
longer median time before the development of PTLD than those of previous reports.
Careful monitoring was needed after allogeneic hematopoietic stem cell transplan-
tation for PTLD. 
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included age, sex, transplanted organ, time from transplan-
tation to diagnosis of PTLD, pathology, EBV status in pathol-
ogy, tumor stage, performance status, extent of extranodal
disease, B symptoms, serum LDH level, graft organ involve-
ment, treatment method, and clinical response to treatment.
EBV detection methods included EBV-LMP (latent membrane
protein), EBV polymerase chain reaction or Epstein Barr
encoded RNA (EBER) in situ hybridization in accordance
with the availability in the hospitals. Staging was performed
according to the criteria of the Ann Arbor system and the
histological subgroups were classified according to WHO
classification. This study was approved by the institutional
review board of Hanyang University Hospital, Asan Medi-
cal Center, Soonchunhyang University Hospital, Busan Paik
Hospital, and Pusan National University Hospital. 
Overall survival was measured from the date of diagnosis
of PTLD to the date of death or last follow-up. Survival
curves were estimated using the Kaplan-Meier method.
RESULTS
Patient characteristics 
Fourteen patients with monomorphic PTLD were identi-
fied from 5,817 transplant recipients. The types of organ trans-
plantation included renal (10 cases, 71.4%), liver (1 case,
7.2%), and allogeneic stem cell (3 cases, 21.4%). The over-
all incidence rate of monomorphic PTLD was 0.24%. The
incidence rates of monomorphic PTLD according to the trans-
planted organ were 0.35% in kidney (10/2,880), 0.045% in
liver (1/2,207), and 0.41% (3/730) in allogeneic stem cell
transplantation. Patient characteristics are summarized in
Table 1. The study group included 11 men and three women,
and the median age at the time of PTLD diagnosis was 42.6
yr (range 24-60). All solid organs were obtained from living
donors. The initial diagnosis of three patients who underwent
allogeneic stem cell transplantation included 2 cases of aplas-
tic anemia and one case of hemophagocytic syndrome. The
median time between the transplant and diagnosis of PTLD
was 85.8 months. All cases of PTLD after allogeneic hema-
topoietic stem cell transplantation occurred within 1 yr after
transplantation (early onset PTLD), whereas the majority of
PTLD after solid organ transplantation (10/11) occurred after
1 yr (late onset PTLD). The most common disease type was
diffuse large B cell lymphoma (50.0%), followed by periph-
eral T cell lymphoma (28.6%), Hodgkin’s disease (14.3%),
and one case of anaplastic large cell lymphoma. One patient
had involvement of the graft organ and seven (50%) patients
had extranodal involvement, most commonly in the liver
(n=3). Five patients were classified as stage IV. Nine patients
had elevated serum LDH, and ten patients demonstrated EBV
positivity in the tumor. In EBV negative cases, two patients
were diagnosed as diffuse large B cell lymphoma, one patient
diagnosed with peripheral T cell lymphoma, and remaining
diagnosed as anaplastic large cell lymphoma. According to
the International Prognostic Index, six patients were low risk
(42.9%), six patients were low-intermediate risk (42.9%),
and two patients were high risk (14.2%).
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PTLD, Post-transplant lymphoproliferative disorders; EBV, Epstein-Barr virus; IPI, international prognostic index; HD, Hodgkin’s disease; DLBCL, diffuse
large B cell lymphoma; PTLD, peripheral T cell lymphoma; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; R-CHOP, rituximab, cyclophos-
phamide, adriamycin, vincristine, prednisone; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; CR, complete response; PR, partial
response; PD, progressive disease.
Age
(yr) 
Sex 
Transplanted
organ
Pathology 
Time to
PTLD
(month)
EBV IPI Stage Treatment Response 
Last status 
(survival duration)
No
1 41 M Kidney HD 116.7 + 0 IIB ABVD, radiation CR CR, alive (46.5 mon)
2 60 M Kidney DLBCL 11.4 + 2 IA R-CHOP, radiation CR CR, alive (42.7 mon)
3 42 F Kidney DLBCL 95.1 - 0 IIA CHOP CR CR, alive (63.4 mon)
4 33 M Kidney DLBCL 90.2 + 2 IVB CHOP CR CR, death (14.7 mon)
5 46 M Kidney DLBCL 110.2 + 4 IVA R-CHOP PR Not CR, death (9.2 mon)
6 44 M Kidney PTCL 117.2 + 2 IIIA CHOP CR CR, alive (36.6 mon)
7 56 M Liver  DLBCL 43.5 + 0 IIA R-CHOP CR CR, alive (30.3 mon)
8 37 F Kidney PTCL 29.8 + 1 IIA CHOP CR Not CR, death (20.8 mon)
9 25 M Bone marrow HD 5.0 + 1 IIA ABVD, radiation PR Not CR, alive (10.5 mon)
10 31 M Kidney PTCL 81.4 - 2 IVB CHOP PD Not CR, death (7.3 mon)
11 55 M Kidney Anaplastic  182.0 - 0 IA CHOP, radiation CR CR, alive (61.4 mon)
large cell
12 24 M Bone marrow DLBCL 5.9 + 4 IVB R-CHOP Not  Not CR, death (1.5 mon)
determined
13 44 F Bone  marrow DLBCL 5.8 - 2 IVA R-CHOP CR CR, alive (15.5 mon)
14 60 M Kidney PTCL 174.7 + 2 IIIA CHOP CR CR, alive (9.9 mon)
Table 1. Patient characteristicsTreatment and outcome
Administration of immunosuppressive agents was reduced
in all patients except for one patient who was not receiving
immunosuppressive treatment at the time of diagnosis because
the grafted organ had already been rejected. Fourteen patients
were treated with combination systemic chemotherapy as fol-
lows: CHOP (cyclophosphamide, adriamycin, vincristine,
prednisone; n=6), R-CHOP (rituximab, cyclophosphamide,
adriamycin, vincristine, prednisone; n=5), ABVD (adriamy-
cin, bleomycin, vinblastine, dacarbazine; n=2), and CHOP
followed by autologous stem cell transplantation (n=1). Four
patients received radiation therapy. 
Because one patient died from infection during chemother-
apy, 13 patients were assessed for response analysis. The over-
all response rate was 92.3%; 10 patients achieved complete
response (CR) and two achieved partial response (PR). Among
the 10 patients who achieved CR, one patient subsequently
suffered relapsed diffuse large B cell lymphoma at 11.3 months.
For the two patients who achieved PR, one patient diagnosed
with Hodgkin’s disease was treated with four cycles of ABVD
followed by radiation therapy (4,400 cGy) and remained in
a state of PR at the time of the last follow up. The other pati-
ent diagnosed with diffuse large B cell lymphoma died due
to disease progression. Among 11 solid organ transplanta-
tions, nine patients preserved graft function. 
The median follow-up period for surviving patients was
36.6 months. There were five deaths during follow-up (35.7
%): three due to infection and two due to disease progression.
Nine patients were still alive (8 CR, 1 PR) at the time of the
last follow-up. The median survival was not reached and 3-
yr survival rate was 59.9% (Fig. 1). 
DISCUSSION
In this retrospective analysis the incidence rate of mono-
morphic PTLD was 0.24% and the median time between
the transplant and diagnosis of PTLD was 85.8 months. Four
out of 14 patients (29%) had EBV-negative PTLD. 
The incidence rate of this study was lower than those in
previous reports. This might be because our study included
only adult monomorphic PTLD patients, and PTLD is more
common in children than in adults. In addition, the majori-
ty of patients in our study underwent kidney or liver trans-
plantation (5,129/5,817), and the incidence of PTLD is the
lowest for recipients of renal or liver allografts and the high-
est for heart-lung, lung, or intestinal allografts (1, 3). Previ-
ous studies on PTLD typically included all PTLD types, from
early lesions to monomorphic PTLD, and the incidence of
monomorphic PTLD is obviously lower than the overall inci-
dence rate; for example, in one report with an overall inci-
dence rate of 1.2%, the incidence rate of monomorphic PTLD
was only 0.48% (4). Finally, since this study was carried out
in a retrospective manner, and since patients with only con-
firmed tissue diagnosis were included in this study, there may
be possibilities that some potential candidates may have been
left out. 
The majority of PTLD occur less than 1 yr after transplan-
tation; however, the median time before the development of
PTLD in our study was longer than those in previous reports.
PTLD that occurs within 1 yr after transplantation is defined
as early PTLD, while that occurs after 1 yr is late PTLD. Early
PTLD is commonly EBV-positive, CD20-positive, and involves
the graft organ (5). In our study, four patients had early PTLD;
three of these were EBV-positive and CD20-positive, and
one patient showed graft organ involvement. 
Recently, a retrospective study was published which stat-
ed the clinical characteristics of PTLD of kidney transplan-
tation in Korea (6). From 2,630 renal transplant recipients,
eleven patients were diagnosed with PTLD. Of these, 10 were
monomorphic PTLD, and the incidence of monomorphic
PTLD was 0.38%. The mean time interval between the time
of transplantation and diagnosis of PTLD was 126.6 months.
This report also represented low incidence rate and long time
interval, which is similar to our results.
Our study revealed that all cases of PTLD after allogeneic
hematopoietic stem cell transplantation (HSCT) were early
PTLD, whereas the majority of PTLDs after solid organ trans-
plantation (10/11) were late PTLD. Hou et al. reported that
the majority of PTLD after allogeneic HSCT occurred with-
in 6 months (7). In their study, the overall mortality rate was
92%, and the major causes of death were disease progression
and infection. In addition, pulmonary PTLD showed an agg-
ressive clinical course and poor response to therapy (7). Our
study included three patients who received allogeneic HSCT;
their time before the development of PTLD was 5.0, 5.8,
and 5.9 months, respectively. Of these, one patient had EBV-
associated PTLD (diffuse large B cell lymphoma) with pul-
monary involvement. Although the patient was treated with
R-CHOP, he died from infection 40 days after chemotherapy.
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Fig. 1. Overall survival for all patients.
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Time (months)Most cases of PTLD are associated with EBV infection. In
the immunosuppressed state, suppression of T-cell activity
interferes with immune surveillance and allows the prolifer-
ation of latently infected B lymphocytes, and the prolifera-
tion of a malignant B cell clone results in lymphoma (8, 9).
However, the incidence of EBV-negative PTLD appears to be
increasing, and recent reports showed that 20-30% of PTLD
cases were EBV-negative. EBV-negative PTLDs occur later
than EBV-positive cases, have a higher proportion of mono-
morphic PTLD, and show a more aggressive clinical course
(10, 11). Although the pathogenesis of EBV-negative PTLD
remains to be determined, changes in the immunosuppres-
sive regimens and new, unidentified infectious agents might
play a role (10). In our study, four cases were EBV-negative;
among these, three patients developed PTLD more than 5 yr
after transplantation. 
Since monomorphic PTLD fulfill the criteria for one of the
recognized types of lymphoma, it is difficult to differentiate
between monomorphic PTLD and de novo lymphoma in pati-
ents who underwent transplantation. It could be a reasonable
option to consider monomorphic PTLD if it contains pleo-
morphism of the transformed cells, variability of cell size, and
EBV positive cells (3).
There is no consensus on the best approach to the treatment
of PTLD. Reduction of immunosuppressive therapy is the
most common initial approach. Other treatment strategies
for PTLD included antiviral therapy, systemic chemothera-
py, rituximab, interferon a, and radiation therapy (1); how-
ever, the treatment outcome and survival of PTLD patients
remains poor. In particular, monomorphic PTLD requires
more aggressive treatment strategies because of its poor prog-
nosis. In our study, all patients received combination chemo-
therapy, and the overall response rate was 92.3%. Although
this study showed a better response rate than other reports,
five of the 14 patients died due to infection or disease pro-
gression. 
Our study has following limitations: the clinical data were
analyzed retrospectively and a relatively small number of
patients were included. Nevertheless, our results provide fur-
ther information on the clinical manifestation, treatment,
and outcomes of monomorphic PTLD. Our results showed
that a lower incidence rate and a longer median time before
the development of PTLD than those of previous reports.
However, all cases of PTLD after allogeneic HSCT occurred
within 1 yr after transplantation, therefore careful monitor-
ing must be needed in this particular group of patients. Com-
pared with previous reports, our study showed better response
rate and survival, and this might be due to the fact that all
our patients received combination chemotherapy. In this aspect,
we suggest that monomorphic PTLD could lead to a better
outcome with an aggressive combination treatment strategies.
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